

Growth Disorder Enrollment Form Phone: 877-437-9012 Fax: 877-309-0687

☐ New to Therapy	
☐ Current Therapy	

Customer Information	Clinical Information and Prescription
Customer Name: Sex: M or F Caregiver: Address: State: Zip: Zip: State: Zip: State: Zip: State: Zip: Zip: State: Zip:	Diagnosis: ☐ E23.0 Hypopituitarism ☐ E34.3 Short Stature due to Endocrine Disorder ☐ R62.52 Short Stature (child) ☐ Description: Date of Diagnosis or Years with Disease: Patients Allergies:
Home Phone: Work Phone: Work Phone: Please attach copy of front and back of patient's prescription insurance card(s) if applicable Insurance Company Name: Insurance Company Phone: Policy holder:	Latex allergy: Patient Height: Patient Height:
Policy holder Employer: Relationship to Patient: ID#Group# RxBIN:RxPCN:	Expected First Dose Date: Injection Instruction needed: □Yes □No □ Genotropin® (somatropin [rDNA] for injection) □ Cartridge (for use in PEN or MIXER Device): □ 5mg □ 12mg □ MiniQuick Device: □ 0.2mg □ 0.4mg □ 0.6mg □ 0.8mg □ 1.0mg □ 1.2mg □ 1.4mg □ 1.6mg □ 1.8mg □ 2.0mg
Prescriber Information Practice/ Organization Name: Prescriber Name: Address:	 ☐ Humatrope® (somatropin [rDNA] for injection) ☐ Cartridge for use in the HumatroPen®: ☐ 6mg ☐ 12mg ☐ 24mg ☐ 5mg Vials
City: Zip: Phone#: Fax#: DEA# NPI#	□ Norditropin® (somatropin [rDNA] for injection) FlexPro® Pen Device □ 5mg/1.5ml □ 10mg/1.5ml □ 15mg/1.5ml □ 30mg/3ml
License#:Medicaid UPIN#: Physician Specialty: Date Shipment Needed:	 ☐ Omnitrope® (somatropin [rDNA] for injection) ☐ Pen Device: ☐ 5mg ☐ 10mg ☐ 5.8mg Vial
Ship to: Patient Prescriber Other: Shipment Address:Attn: City:State:Zip: If shipped to the prescriber's office, Prescriber accepts on behalf of patient for administration in office.	□ Saizen® (somatropin [rDNA] for injection) □ Vial w/ bacteriostatic water for Inj 0.3%: □ 5mg □ 8.8mg □ 8.8mg click.easy® cartridge with Sterile Water for Inj 0.3%
Privacy & Confidentiality of Information Notice: This communication may contain non-public, confidential, or legally privileged information intended for the sole use of the designated recipient(s). If you are not the intended recipient, or have received this communication in error, please notify the sender immediately by reply email or by telephone at the number stated above and delete all copies of this communication, including any attachments, without reading them or saving them to disk. If you are the intended recipient, you must secure the contents of this communication in accordance with all applicable state or federal requirements related to the privacy and confidentiality of information, including the HIPAA Privacy guidelines.	Dose: Inject mg subcutaneously days per week; or Inject mg/kg subcutaneously days per week Quantity Prescribed: □ QS 30 days □ Other: Refills Authorized:□0 □1 □3 □6 □11 □ Prescriber Signature: X Date://